title: Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.
abstract: OBJECTIVE
  To study the ability of positron emission tomography (PET) using 18-fluorodeoxyglucose (FDG) to distinguish between benign and malignant disease in exudative pleural effusions and pleural thickening.
  
  
  METHODS
  Prospective study of 98 consecutive patients presenting with either pleural thickening or an exudative pleural effusion.
  
  
  METHODS
  Department of pulmonary medicine of a university hospital.
  
  
  METHODS
  FDG-PET was performed on each subject before invasive procedures were used to determine the etiologic diagnosis. FDG-PET data were analyzed by visual interpretation.
  
  
  RESULTS
  Sixty-three of 98 patients were found to have malignant pleural disease after histologic analysis. Sixty-one of 63 patients with histologically confirmed malignant disease showed FDG uptake within the area of pleural thickening. Uptake was graded as intense in 51 cases and moderate in 10 cases. Only two patients with malignant pleural disease did not show increased FDG uptake. FDG-PET imaging showed an absence of FDG uptake, and correctly classified 31 of 35 benign lesions. For the remaining four lesions, intense FDG uptake was seen in one case of parapneumonic effusion, while moderate and localized uptake was observed in one parapneumonic, one tuberculous, and one uremic pleurisy. The sensitivity of the method to identify malignancy was 96.8% with a negative predictive value of 93.9%, while its specificity was 88.5% and its positive predictive value was 93.8%.
  
  
  CONCLUSIONS
  Our results suggest that FDG-PET is an effective tool for differentiating between benign and malignant pleural diseases.
authors.affiliation: Department of Pulmonary Medicine, CHU Sart Tilman B35, B-4000 Liège, Belgium. bduysinx@swing.be
authors.forename: Bernard
authors.initials: B
authors.lastname: Duysinx
authors.forename: Delphine
authors.initials: D
authors.lastname: Nguyen
authors.forename: Renaud
authors.initials: R
authors.lastname: Louis
authors.forename: Didier
authors.initials: D
authors.lastname: Cataldo
authors.forename: Tarik
authors.initials: T
authors.lastname: Belhocine
authors.forename: Pierre
authors.initials: P
authors.lastname: Bartsch
authors.forename: Thierry
authors.initials: T
authors.lastname: Bury
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001707:Biopsy, Needle; D016001:Confidence Intervals; D003937:Diagnosis, Differential; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000494:pharmacology*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010995:Pleural Diseases / Q000000981:diagnostic imaging* / Q000473:pathology*; D010996:Pleural Effusion / Q000000981:diagnostic imaging / Q000473:pathology; D010997:Pleural Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D014055:Tomography, Emission-Computed / Q000379:methods*
chemical_list: D019788:Fluorodeoxyglucose F18